In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety […]
Report urges mental health decision makers and advocates to step up commitment and action to change attitudes, actions and approaches to mental health, its determinants […]
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced […]
Funding round led by Advent Life Sciences. New investors include Emerson Collective, SoftBank Vision Fund 2, British Patient Capital, Mubadala and the Minderoo Foundation. Proceeds […]
…to Fill Industry Gap in Process Analytical Technologies for Downstream Processing Merck today announced that it has entered a collaboration with Agilent Technologies to advance […]
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]
and Other Virus Variants Effectively Replenished after 3rd and 4th COVID-19 Vaccination 12 / 2022 Two vaccinations with Comirnaty do not lead to adequate antibody […]
…..to Commercialize Efgartigimod Across Europe and Israel Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in […]
Copyright © 2023 | WordPress Theme by MH Themes
